When the Poor Man's Discount Finds Its Way Into the Rich Institution's Ledger

The Washington Examiner reports that Congress created the 340B program to help hospitals serving poor patients purchase prescription drugs at sharply reduced prices — a sensible arrangement, provided the savings find their way to the patient rather than stopping at the administrator's desk. The trouble, as the Examiner describes it, is that many hospitals have turned the discount into a profit mechanism, capturing the spread between the low acquisition cost and the full reimbursement price, while the patients for whom the program was designed see little or no relief at the counter.

I am no stranger to this pattern. In my printing days I watched more than one public contract — set up by the legislature for the public benefit — migrate, by slow and polite degrees, into the private benefit of the contractor. The instrument was sound; the oversight was absent. A discount is only a discount to the patient if it travels the full distance from the wholesaler to the sick man's bill. Any gap in that journey is, by my reckoning, a quiet transfer of wealth from the taxpayer and the poor to the institution that was already better situated than either.

The Washington Examiner's headline calls this "stealing," which is a sharp word, and I will not quarrel with sharpness when the facts support it. What I will add is the household-economy framing: when a hospital acquires a drug for, say, twenty dollars under a federal discount and bills the insurer or the patient eighty dollars for the same drug, the sixty-dollar difference is not profit earned by industry or invention — it is a toll extracted from a road that the public built and paid for. The tradesman who builds a road and then charges travelers who were promised free passage has not done anything complicated; he has simply helped himself.

The remedy is not complicated either, though it is politically inconvenient for the institutions involved. Any program that grants a price preference must require an accounting of where the saving went. If the hospital cannot show that the 340B discount reduced the cost to an eligible low-income patient, the discount should not have been available in the first place. This is not novel regulation; it is the ordinary condition of any public subsidy: you receive the benefit in exchange for performing the purpose. (This conclusion is my inference from the principle; the Examiner's report does not detail a specific legislative remedy.)

I spent my later years petitioning against arrangements that extracted value from those least able to defend themselves — and I will confess I did not always see such arrangements clearly in my earlier life. I see them clearly enough now. The 340B program is, in principle, exactly the sort of civic mechanism a republic should maintain: using collective purchasing power to protect its most vulnerable members. That is worth preserving. What is not worth preserving is the fiction that the mechanism is working when the evidence suggests the savings are pooling at an institutional level and never reaching the bedside.

A counsel for the working person: If you receive a prescription through a hospital outpatient pharmacy, ask directly whether the facility participates in 340B and what your out-of-pocket cost would be compared to a retail pharmacy. The answer may surprise you — and the asking is itself a form of civic pressure that costs nothing.